Acumen Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABOS Nasdaq 8731 http://www.acumenpharm.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript - May 17th, 2022 2:00 am
Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights - May 16th, 2022 8:05 pm
Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022 - May 11th, 2022 9:08 pm
Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease - Apr 27th, 2022 12:00 pm
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript - Apr 2nd, 2022 4:00 am
We're Hopeful That Acumen Pharmaceuticals (NASDAQ:ABOS) Will Use Its Cash Wisely - Apr 1st, 2022 9:01 pm
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights - Mar 28th, 2022 8:05 pm
Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022 - Mar 16th, 2022 8:15 pm
Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last year - Dec 30th, 2021 9:16 am
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital - Nov 25th, 2021 12:35 pm
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights - Nov 15th, 2021 1:00 pm
Acumen Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 8th, 2021 1:00 pm
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Nov 2nd, 2021 12:00 pm
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease - Oct 7th, 2021 12:00 pm
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth - Oct 1st, 2021 10:05 am
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights - Aug 16th, 2021 8:05 pm
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering - Jul 1st, 2021 2:44 am